leisure time -WSS

leisure time

author：knowledge 2025-08-26 02:45:32 - browse：24

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： 2023 STAT Wunderkinds: get to know the winners

explore

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Why don't Americans have at

STAT Readout Newsletter: Today's biggest biotech updates

Why health workers in Gaza are injured or die at high rates

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

knowledge

leisure time

hotspot

Walensky prepares to leave CDC — and Congress — behind

Why don't Americans have at

Hollywood unions extend contract negotiations for actors

Eli Lilly expects to double planned employment in Boston center

Apple is now the first public company to be valued at $3 trillion

Report cites 'urgent' need to recruit more diverse clinical trial participants

In Memoriam: Notable people who died in 2023

Report cites 'urgent' need to recruit more diverse clinical trial participants

State Dept. review finds Biden bears some blame for Afghanistan failures

Eli Lilly expects to double planned employment in Boston center

entertainment

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Too many hospitalized Covid

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Too many hospitalized Covid

Medicare reduced heart disease by changing how it pays doctors

Studies point to risks of excluding people with obesity from drug trials

knowledge

explore

entertainment

Wikipedia